Sodeeq Adewale Babalola

Mr. Sodeeq Adewale Babalola

Ahmadu Bello University, Zaria, Kaduna, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Pharmaceutical Fronts
Verified
Journal Article
Open access
PDF file
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
NINosakhare Igie
Nosakhare Igie
IOIsaiah Odeyemi
Isaiah Odeyemi
Nonsteroidal anti-inflammatory drugs (NSAIDs) and coxibs are traditional medicines for the treatment of inflammation, yet associated with serious side effects. Hence, the need for discovering novel compounds with valuable clinical benefits is of great importance. In this study, 18 derivatives of p-nitrophenyl hydrazones were docked against COX-2, 5-LOX, and H+/K+ ATPase, followed by predicting their drug-likeness and absorption, distribution, metabolism, and excretion (ADME) properties. From the docking analysis, 1-(4-nitrophenyl)-2-[(3,4,5-trimethoxyphenyl)methylidene]hydrazine (3), 4-hydroxy-2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]thiochroman-1,1-dioxide (6), 4-methoxy-2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]thiochroman-1,1-dioxide (8), 2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]-4-(trifluoromethyl)thiochroman-1,1-dioxide (11), 4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]benzenesulfonamide (13), 4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]-3-(trifluoromethyl)benzenesulfonamide (14), 5-methyl-6-{4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]phenyl}-2,3,4,5-tetrahydropyridazin-3-ol (16), and 5-methyl-6-{4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]phenyl}-4,5-dihydropyridazin-3(2H)-one (17) showed promise as potent multi-target inhibitors of COX-2, 5-LOX, and H+/K+ ATPase. These compounds are less COX-2 selective than the control (celecoxib). “Drug-likeness” analysis passed Lipinski's, Egan's, Veber's, Muegge's, and Ghose's rules. The compounds also passed Pfizer and GSK rules, as well as golden triangle's rule for identification of potent and metabolically stable drugs. The pharmacokinetic profiles of the compounds were excellent, safe, and compliant with their potential anti-inflammatory activity. The results of the study can be used for future optimization of those derivatives for better molecular interactions against COX-2, 5-LOX, and H+/K+ ATPase, and inflammation-effective inhibition. Received: 09 June 2022 Accepted: 03 November 2022 Article published online: 27 December 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

15 March 2023 in Pharmaceutical Fronts
Verified
Journal Article
Open access
PDF file
MYMuhammad H. Yahya
Muhammad H. Yahya
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
AIAbdullahi Y. Idris
Abdullahi Y. Idris
AHAsmau N. Hamza
Asmau N. Hamza
NINosakhare Igie
Nosakhare Igie
AOAmina B. Olorukooba
Amina B. Olorukooba
Malaria remains a febrile infection of public health concern in many countries especially tropical countries in Africa and certain countries in Southern and North America such as Brazil, Costa Rica, Mexico, Dominican Republic, Colombia, and Ecuador. Hence this has made research into this area paramount. Acetophenones are active fragments in many compounds with promising antimalarial activity, such as chalcones. The aim of the present study was to investigate antimalarial activity of 3,5-diprenyl acetophenone (I) and 5-diprenyl acetophenone (II) in in vivo. In this study, compounds I and II were synthesized using an aromatic substitution reaction. The in-vivo antimalarial potential of compounds I and II was analyzed in Plasmodium berghei-infected mice. Our data showed that compound I (25, 50, and 100 mg/kg) had promising antimalarial activity, with parasitemia inhibited rate being 68.03, 65.16, and 69.75%, respectively. Compound II dose-dependently inhibited parasitemia levels, it demonstrated an infinitesimally higher activity (72.12%) when compared with compound I (69.75%) at 100 mg/kg dose. The two compounds passed the rule of three, Lipinski's rule of five, predicted plausible pharmacokinetic profile (ADME), and apparent safety profile, and demonstrated drug-like fragments. The study provided guidance in exploring novel antimalarial compounds based on the scaffolds of prenylated acetophenones.

14 September 2022 in ChemRxiv
Verified
Preprint
Open access
PDF file
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
NINosakhare Igie
Nosakhare Igie
IOIsaiah Odeyemi
Isaiah Odeyemi
We designed novel p-nitrophenyl hydrazones as multi-target inhibitors of COX-2, 5-LOX, and H+/K+ ATPase in a bid to overcome side effects associated to NSAIDs and coxibs. Specifically, compounds 1-(4-nitrophenyl)-2-[(3,4,5-trimethoxyphenyl)methylidene] hydrazine (3), 4-hydroxy-2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]thiochroman-1,1-dioxide (6), 4-methoxy-2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]thiochroman-1,1-dioxide (8), 2-methyl-6-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]-4-(trifluoromethyl)thiochroman-1,1-dioxide (11), 4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]benzenesulfonamide (13), 4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]-3-(trifluoromethyl)benzenesulfonamide (14), 5-methyl-6-{4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]phenyl}-2,3,4,5-tetrahydropyridazin-3-ol (16), and 5-methyl-6-{4-[(2-(4-nitrophenyl)hydraz-1-ylidene)methyl]phenyl}-4,5-dihydropyridazin-3(2H)-one (17) indicated promise as potent multi-target inhibitors of COX-2, 5-LOX, and H+/K+ ATPase with potential anti-inflammatory activity devoid of adverse effects of NSAIDs. Interactions with important amino acids which are key for ant-inflammatory activity and proton pump inhibition were noticed. All the compounds are less COX-2 selective compared to celecoxib. These compounds in addition have shown druglike physicochemical properties, passed Lipinski’s, Egan’s, Veber’s, Muegge’s and Ghose’s rules for druglike small molecules and orally bioavailable drugs. The compounds also passed golden triangle’s rule for potent and metabolically stable drugs. Also, these compounds passed Pfizer and GSK rules. The compounds also indicated excellent pharmacokinetic profiles complementing their potential anti-inflammatory activity with apparent safety profiles.

29 March 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
NINosakhare Igie
Nosakhare Igie
AIAbullah Idris
Abullah Idris
YSYeken Sanni
Yeken Sanni
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
LBLateef Bakare
Lateef Bakare
We conducted a comparative study on the development of two synthetic methods. The solvent-free synthesis is a green chemistry method developed in a bid to ameliorate environmental adverse effects of the conventional solvent-based synthesis. The synthesis of novel dichloro and polymethoxy p-nitrophenylhydrazones through solvent free technique gave moderate to high yields which were however lower than those of the solvent-based method. The established solvent-free approach has several benefits, including universality and simplicity of the approach, catalyst-free conditions, non-use of an organic solvent, quick reaction time, fast and efficient workup, and un-solvated pure products in moderate to high yields.
1

24 May 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
HMHayatudeen Muhammad
Hayatudeen Muhammad
AIAbdullah Idris
Abdullah Idris
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
Malaria remain an epidermic infectious disease that is ravaging the world most especially sub-Sahara Africa. Due to the prevalence of Plasmodium parasites that are resistant to first-line antimalarial drugs, it is urgently necessary to create new scaffolds and find strategies to overcome drug resistance. Chalcones are well-known, uncomplicated analogs that may be easily produced using a variety of techniques and are widely present in natural products. Utilizing in silico tools, we developed new antimalarial agents from active synthetic and natural product fragments, and then we assessed their pharmacokinetics and pharmacodynamic profiles as therapeutic molecules against the biological targets of the parasite that causes the deadly type of malaria. In this research, active fragments from prenylated and quinolinyl chalcones with known antimalarial characteristics were combined via molecular hybridization. Four enzymes that have been implicated to the spread of malaria are used as the biological targets in the docking simulation for the ligands (prenylated-quinolinyl chalcone hybrids). Receptor-ligand complexes were viewed using Discovery Studio Visualizer 2017 and Chimera. Web-based tools (Moftsoft, SwissADME, Admetlab, and AdmetSAR 1 and 2) were utilized for drug-likeness and ADME prediction. The hybridized active segments created a brand-new scaffold with 169 new prenylated-quinolinyl chalcones. Post-docking studies found significant interactions between the drugs and the used targets. At least 25 of the compounds exhibit high affinities for the targets (-9.4 to -7.5 kcal/mol-1). The selected compounds had interesting ADME and drug-like properties. The compounds were qualified as possible antimalarial drugs due to their realistic pharmacokinetic and pharmacodynamic characteristics as well as their prospective antimalarial activity.

12 April 2022 in ChemRxiv
Verified
Preprint
Open access
PDF file
SBSodeeq Adewale Babalola
Sodeeq Adewale Babalola
AGAdeyemi Gabriel
Adeyemi Gabriel
The preliminary screening of phytochemical constituents of extracts of Xylopia aethiopica was evaluated. The n-hexane extract revealed the presence of terpenoids, alkaloids, and steroids, while the presence of alkaloids, terpenoids, saponins, steroids, and phenolics was indicated in ethyl acetate extract, and the methanol extract contained tannins, flavonoids, phenolics, terpenoids, saponins, alkaloids, steroids. The medicinal property of the extracts was investigated using in-vitro antimicrobial assays. The hexane extract indicates potent activity against Pseudomonas aeruginosa with MIC of 100 mg/ml and ZI of 20 mm. Methanol and ethyl acetate extracts had inhibitory activities against Candida albican with MIC of 100mg/ml while the standard antibiotics had no inhibitory activities against Candida albican, suggesting that these extracts contain certain phytochemical that are active against Candida albican. Saponins which are constituents of methanol and ethyl acetate extracts from the phytochemical screening, are known to be antifungal, especially against Candida albican. This suggests that the presence of saponins in both ethyl acetate and methanol extracts may be responsible for the inhibitory activities against Candida albican.